Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Altimmune Announces Initiation Of 12-week Phase 1b Trial Of Pemvidutide In Subjects With Non-Alcoholic Fatty Liver Disease


Benzinga | Oct 4, 2021 07:04AM EDT

Altimmune Announces Initiation Of 12-week Phase 1b Trial Of Pemvidutide In Subjects With Non-Alcoholic Fatty Liver Disease






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC